Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 484 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... February 18, 2020 ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A... December 29, 2021 Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node... August 31, 2021 Bride Learns Sign Language, Surprises Groom’s Deaf Parents & Signs Her... January 11, 2022 Load more HOT NEWS ESMO Releases New Patient Guide in Hepatocellular Carcinoma Children’s cancer charities team up for tomorrow’s treatments Black Patients Are More Likely to Die of Cancer—Here’s How One... EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin
